Page last updated: 2024-12-07
sennidin a
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
dihydroxydianthrone: aglycone of senna glycosides [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 92826 |
| CHEMBL ID | 5197294 |
| SCHEMBL ID | 17166294 |
| MeSH ID | M0062119 |
Synonyms (21)
| Synonym |
|---|
| sennidin a |
| unii-o8793fim31 |
| (9,9'-bianthracene)-2,2'-dicarboxylic acid, 9,9',10,10'-tetrahydro-4,4',5,5'-tetrahydroxy-10,10'-dioxo-, (r*,r*)-(+)- |
| einecs 211-371-5 |
| (r*,r*)-(+)-9,9',10,10'-tetrahydro-4,4',5,5'-tetrahydroxy-10,10'-dioxo(9,9'-bianthracene)-2,2'-dicarboxylic acid |
| dihydroxydianthrone |
| o8793fim31 , |
| (9,9'-bianthracene)-2,2'-dicarboxylic acid, 9,9',10,10'-tetrahydro-4,4',5,5'-tetrahydroxy-10,10'-dioxo-, (9r,9'r)-rel-(+)- |
| (9,9'-bianthracene)-2,2'-dicarboxylic acid, 9,9',10,10'-tetrahydro-4,4',5,5'-tetrahydroxy-10,10'-dioxo-, (r*,r*)-(+)- |
| SCHEMBL17166294 |
| CHEMBL5197294 |
| 9,9'-bianthracene]-2,2'-dicarboxylic acid, 9,9',10,10'-tetrahydro-4,4',5,5'-tetrahydroxy-10,10'-dioxo-, (9r,9'r)- |
| AKOS030573520 |
| (9r,9'r)-4,4',5,5'-tetrahydroxy-10,10'-dioxo-9,9',10,10'-tetrahydro-[9,9'-bianthracene]-2,2'-dicarboxylic acid |
| A14836 |
| Q27285465 |
| CS-0027785 |
| HY-N6936 |
| sennidina |
| DTXSID601318488 |
| FS-10383 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Using the Caco-2 human colonic cell line as an in vitro model of the human intestinal mucosal barrier, the bioavailability of dianthrones was studied in apical to basolateral (absorptive) and basolateral to apical (secretive) direction." | ( Transport of sennosides and sennidines from Cassia angustifolia and Cassia senna across Caco-2 monolayers--an in vitro model for intestinal absorption. Avula, B; Ganzera, M; Khan, IA; Khan, SI; Stuppner, H; Waltenberger, B, 2008) | 0.35 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1847095 | Inhibition of Hepatitis C virus NS3 helicase measured by fluorescence helicase assay | 2021 | European journal of medicinal chemistry, Nov-05, Volume: 223 | Recent advances of quinones as a privileged structure in drug discovery. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 21.65
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.65) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||